- Home
- ISD vs RGNX Comparison
ISD vs RGNX Comparison
Compare ISD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISD
- RGNX
- Stock Information
- Founded
- ISD 2012
- RGNX 2008
- Country
- ISD United States
- RGNX United States
- Employees
- ISD N/A
- RGNX N/A
- Industry
- ISD Trusts Except Educational Religious and Charitable
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ISD Finance
- RGNX Health Care
- Exchange
- ISD Nasdaq
- RGNX Nasdaq
- Market Cap
- ISD 472.3M
- RGNX 451.1M
- IPO Year
- ISD N/A
- RGNX 2015
- Fundamental
- Price
- ISD $14.63
- RGNX $9.09
- Analyst Decision
- ISD
- RGNX Strong Buy
- Analyst Count
- ISD 0
- RGNX 8
- Target Price
- ISD N/A
- RGNX $28.50
- AVG Volume (30 Days)
- ISD 127.1K
- RGNX 535.6K
- Earning Date
- ISD 01-01-0001
- RGNX 11-05-2025
- Dividend Yield
- ISD 9.69%
- RGNX N/A
- EPS Growth
- ISD N/A
- RGNX N/A
- EPS
- ISD N/A
- RGNX N/A
- Revenue
- ISD N/A
- RGNX $155,782,000.00
- Revenue This Year
- ISD N/A
- RGNX $203.27
- Revenue Next Year
- ISD N/A
- RGNX $0.58
- P/E Ratio
- ISD N/A
- RGNX N/A
- Revenue Growth
- ISD N/A
- RGNX 74.95
- 52 Week Low
- ISD $10.98
- RGNX $5.04
- 52 Week High
- ISD $13.17
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- ISD 60.13
- RGNX 50.36
- Support Level
- ISD $14.44
- RGNX $9.35
- Resistance Level
- ISD $14.67
- RGNX $10.08
- Average True Range (ATR)
- ISD 0.08
- RGNX 0.54
- MACD
- ISD -0.01
- RGNX -0.01
- Stochastic Oscillator
- ISD 79.17
- RGNX 30.77
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.